Experimental MegaLT injection targets dangerous low platelets in early trial
NCT ID NCT06534255
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new cell therapy called MegaLT for people with dangerously low platelet counts that don't improve after radiation, chemotherapy, or stem cell transplant. Only 10 participants will receive the injection at different doses to check safety and how the body handles it. The study is not yet recruiting and focuses on finding a safe dose, not proving it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MegaLT injection (a cell therapy)
What this could lead to
If it works, this could point toward a new treatment for dangerously low platelet counts that don't respond to standard care.
What could go wrong
This is a very early, tiny Phase 1 trial with only 10 people. It primarily checks safety, not effectiveness. The treatment may not work or could cause side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, Anhui, 230036, China